Form 4 for JBIO Jade Biosciences, Inc.
Accepted 2023-12-22 00:00:00 ET · period of report 2023-12-20 · accession 0001415889-23-016908 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-22 | 2023-12-13 | JBIO | Gillies Hunter | Chief MEDICAL Off | M - OptEx | $1.74 | +4,000 | 7,251 | +123% | +$6,960 |
| D | 2023-12-22 | 2023-12-20 | JBIO | Gillies Hunter | Chief MEDICAL Off | S - Sale+OE | $19.50 | -4,000 | 3,251 | -55% | -$78.0K |
| DM | 2023-12-22 | 2023-12-20 | JBIO | Gillies Hunter | Chief MEDICAL Off | M - OptEx | $0.00 | -4,000 | 9,023 | -31% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-13 | M | A | 4,000 | $1.74 | 7,251 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-20 | S | D | 4,000 | $19.50 | 3,251 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-12-20 | M | D | 1,076 | $0.00 | 10,027 | D | $1.74 · — to 2030-09-03 | 1,076 Common Stock | (F3) A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-12-20 | M | D | 2,924 | $0.00 | 9,023 | D | $1.74 · — to 2030-09-03 | 2,924 Common Stock | (F2) A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |